NASDAQ:CTOR

Citius Oncology Q3 2026 Earnings Results & Report

Citius Oncology logo
$0.56 +0.01 (+1.79%)
Closing price 04:00 PM Eastern
Extended Trading
$0.55 -0.01 (-0.97%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Citius Oncology missed analyst expectations on both earnings and revenue in its Q3 2026 results, released August 14, 2026. The company reported EPS of -$0.08 versus the -$0.07 consensus estimate, while revenue of $1.49 million fell short of the $2.50 million estimate by $1.01 million.

Earnings Announcement Details

Quarter
Q3 2026
Report Date
Time
Before Market Opens
Conference Call
7:00 AM ET

Citius Oncology EPS Results

Actual EPS
-$0.08
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A
EPS Beat Rate
0 of last 5 quarters

Citius Oncology Revenue Results

Actual Revenue
$1.49 million
Expected Revenue
$2.50 million
Beat/Miss
Missed by -$1.01 million
YoY Revenue Growth
N/A

Upcoming Earnings

Citius Oncology's Q4 2026 earnings is estimated for Thursday, December 17, 2026, based on past reporting schedules, with a conference call scheduled on Wednesday, December 23, 2026 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Citius Oncology Q3 2026 Earnings FAQ

Citius Oncology (NASDAQ:CTOR) reported earnings of -$0.08 per share for Q3 2026, missing the consensus estimate of -$0.07. The report was announced on Friday, August 14, 2026.

Citius Oncology reported revenue of $1.49 million for Q3 2026, against a consensus estimate of $2.50 million.

Citius Oncology's next earnings date is estimated for Thursday, December 17, 2026. MarketBeat tracks confirmed and estimated earnings dates for Citius Oncology on the company's earnings history page.

Citius Oncology Earnings Headlines

Your father's savings lost half their value after 1971.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no debate, no vote, one executive order. Gold tripled within three years and climbed 20x over the following decade. Trump holds that same executive authority today, and his advisors are openly saying a reversal is on the table. There are two ways this plays out - both move gold in the same direction. A free briefing breaks down exactly what Nixon did, why Trump is positioned to act, and how to move your 401k into gold before any announcement - tax free.tc pixel
See More Citius Oncology Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Citius Oncology? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Citius Oncology and other key companies, straight to your email.

About Citius Oncology

Citius Oncology (NASDAQ:CTOR) is a biopharmaceutical company focused on developing and commercializing oncology therapies. Its lead product is LYMPHIR (denileukin diftitox-cxdl), an immunotherapy approved in the United States for adults with relapsed or refractory cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.

LYMPHIR targets cells expressing the interleukin-2 receptor and is intended to treat certain forms of CTCL, a rare non-Hodgkin lymphoma that affects the skin. The company’s commercial activities are centered on making the therapy available to eligible patients in the U.S.

Citius Oncology became a publicly traded company following a business combination involving Citius Pharmaceuticals’ oncology subsidiary and TenX Keane Acquisition. Leonard Mazur, a co-founder and longtime executive of Citius Pharmaceuticals, has served as Citius Oncology’s chief executive officer.

View Citius Oncology Profile